Sinil Kim

9.8k total citations · 3 hit papers
90 papers, 5.6k citations indexed

About

Sinil Kim is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Sinil Kim has authored 90 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 37 papers in Pulmonary and Respiratory Medicine and 20 papers in Oncology. Recurrent topics in Sinil Kim's work include Renal cell carcinoma treatment (23 papers), Fungal Biology and Applications (12 papers) and Cancer Genomics and Diagnostics (11 papers). Sinil Kim is often cited by papers focused on Renal cell carcinoma treatment (23 papers), Fungal Biology and Applications (12 papers) and Cancer Genomics and Diagnostics (11 papers). Sinil Kim collaborates with scholars based in United States, South Korea and Japan. Sinil Kim's co-authors include Brian I. Rini, Brad Rosbrook, Paul Bycott, Katherine Liau, Jamal Tarazi, Peter C. Trask, Robert J. Motzer, Connie Chen, Olivier Rixe and Jay Stoudemire and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Sinil Kim

89 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

2016 682 citations Sinil Kim et al. profile →
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

2013 542 citations Robert J. Motzer, Bernard Escudier et al. profile →
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

2008 494 citations Ezra E.W. Cohen, Lee S. Rosen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sinil Kim United States	29	3.0k	2.4k	1.9k	1.8k	489	90	5.6k
Daniel J. George United States	48	3.3k 1.1×	4.7k 1.9×	2.9k 1.5×	1.9k 1.1×	767 1.6×	255	8.0k
Madappa N. Kundranda United States	16	2.5k 0.9×	1.4k 0.6×	2.4k 1.2×	1.5k 0.8×	901 1.8×	66	5.8k
William G. Cance United States	55	4.2k 1.4×	940 0.4×	2.9k 1.5×	1.8k 1.0×	807 1.7×	174	9.2k
Miguel A. Villalona‐Calero United States	43	2.7k 0.9×	2.1k 0.9×	3.2k 1.6×	1.1k 0.6×	536 1.1×	187	6.4k
X. Cynthia United States	46	3.1k 1.0×	2.8k 1.1×	5.0k 2.6×	2.3k 1.3×	206 0.4×	251	8.8k
Epie Boven Netherlands	45	3.0k 1.0×	2.0k 0.8×	3.3k 1.7×	1.1k 0.6×	403 0.8×	190	7.5k
David F. Jarrard United States	49	4.0k 1.4×	5.0k 2.1×	2.1k 1.1×	2.0k 1.1×	920 1.9×	207	10.0k
Alan So Canada	43	2.2k 0.7×	2.0k 0.8×	1.4k 0.7×	866 0.5×	1.4k 2.8×	200	5.3k
Mayer Fishman United States	37	1.9k 0.7×	1.8k 0.7×	3.1k 1.6×	924 0.5×	962 2.0×	147	6.3k
Yoshiyuki Kakehi Japan	44	2.7k 0.9×	2.7k 1.1×	1.6k 0.9×	805 0.4×	1.9k 3.9×	262	7.0k

Countries citing papers authored by Sinil Kim

Since Specialization

Citations

This map shows the geographic impact of Sinil Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sinil Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sinil Kim more than expected).

Fields of papers citing papers by Sinil Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sinil Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sinil Kim. The network helps show where Sinil Kim may publish in the future.

Co-authorship network of co-authors of Sinil Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Sinil Kim. A scholar is included among the top collaborators of Sinil Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sinil Kim. Sinil Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oh, Youn-Lee, et al.. (2025). Targeted insertion of heterogenous DNA using Cas9-gRNA ribonucleoprotein-mediated gene editing in Ganoderma lucidum. Bioengineered. 16(1). 2458376–2458376. 3 indexed citations

Kim, Sinil, et al.. (2023). Heterokaryosis, the main obstacle in the generation of PPO1-edited Agaricus bisporus by CRISPR/Cas9 system. Scientia Horticulturae. 318. 112095–112095. 12 indexed citations

Kim, Sinil, et al.. (2022). Comparative structural analysis on the mitochondrial DNAs from various strains of Lentinula edodes. Frontiers in Microbiology. 13. 1034387–1034387.

Kim, Sinil, et al.. (2018). Activation of the Mating Pheromone Response Pathway of Lentinula edodes by Synthetic Pheromones. Mycobiology. 46(4). 407–415. 4 indexed citations

Kim, Sinil, et al.. (2018). Diversity of A mating type in Lentinula edodes and mating type preference in the cultivated strains. The Journal of Microbiology. 56(6). 416–425. 15 indexed citations

Kim, Sinil, Yong Seok Lee, Je Chul Lee, et al.. (2016). Novel nuclear targeting coiled-coil protein of Helicobacter pylori showing Ca2+-independent, Mg2+-dependent DNase I activity. The Journal of Microbiology. 54(5). 387–395. 5 indexed citations

Escudier, Bernard, Brian I. Rini, Robert J. Motzer, et al.. (2015). Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 13(4). 328–337.e3. 29 indexed citations

Tortorici, Michael A., Ezra E.W. Cohen, Yazdi K. Pithavala, et al.. (2014). Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemotherapy and Pharmacology. 74(6). 1279–1289. 13 indexed citations

Fruehauf, John P., Jose Lutzky, David H. McDermott, et al.. (2011). Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma. Clinical Cancer Research. 17(23). 7462–7469. 93 indexed citations

10.

Trask, Peter C., Andrew G. Bushmakin, Joseph C. Cappelleri, et al.. (2011). Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. Journal of Cancer Survivorship. 5(3). 255–262. 5 indexed citations

11.

Cohen, Ezra E.W., Lee S. Rosen, Everett E. Vokes, et al.. (2008). Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study. Journal of Clinical Oncology. 26(29). 4708–4713. 494 indexed citations breakdown →

12.

LoRusso, Patricia, Smitha Krishnamurthi, Lisle Nabell, et al.. (2007). Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer. Molecular Cancer Therapeutics. 6. 13 indexed citations

13.

Kim, Sinil, et al.. (1995). A Phase II Trial of Intraperitoneal High-Dose Carboplatin and Etoposide with Granulocyte Macrophage-Colony Stimulating Factor Support in Patients with Ovarian Carcinoma. American Journal of Clinical Oncology. 18(1). 23–26. 14 indexed citations

14.

Hansbrough, John F., et al.. (1995). Soft tissue infection prophylaxis with gentamicin encapsulated in multivesicular liposomes. Critical Care Medicine. 23(1). 84–91. 19 indexed citations

15.

Plaxe, Steven C., James L. Freddo, Sinil Kim, et al.. (1994). Phase I Trial of Cisplatin in Combination with Glutathione. Gynecologic Oncology. 55(1). 82–86. 18 indexed citations

16.

Chatelut, Étienne, et al.. (1994). Sustained-Release Methotrexate For Intracavitary Chemotherapy. Journal of Pharmaceutical Sciences. 83(3). 429–432. 24 indexed citations

17.

Plaxe, Steven C., Patricia S. Braly, James L. Freddo, et al.. (1993). Phase I and Pharmacokinetic Study of Intraperitoneal Ormaplatin. Gynecologic Oncology. 51(1). 72–77. 3 indexed citations

18.

Kim, Sinil. (1993). Liposomes as Carriers of Cancer Chemotherapy. Drugs. 46(4). 618–638. 84 indexed citations

19.

Chatelut, Étienne, Taehee Kim, & Sinil Kim. (1993). A slow-release methotrexate formulation for intrathecal chemotherapy. Cancer Chemotherapy and Pharmacology. 32(3). 179–182. 17 indexed citations

20.

Kim, Sinil, et al.. (1991). Multivesicular liposomes containing bleomycin for subcutaneous administration. Cancer Chemotherapy and Pharmacology. 28(2). 105–108. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact